Half-year report · Q2
2160.TEDINET S100WJCL
Period2025-01-01 → 2025-06-30
Filed2025-08-14
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 48
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥12.3bn | 2025-01-01 → 2025-06-30 | Cons. | Revenue IFRS |
| Revenue | ¥23.6bn | 2024-01-01 → 2024-12-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥11.7bn | 2024-01-01 → 2024-06-30 | Cons. | Revenue IFRS |
| Operating income | −¥1.2bn | 2025-01-01 → 2025-06-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥1.8bn | 2024-01-01 → 2024-06-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | −¥1.4bn | 2025-01-01 → 2025-06-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥238m | 2024-01-01 → 2024-12-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥831m | 2024-01-01 → 2024-06-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | −¥915m | 2025-01-01 → 2025-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥1.1bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥330m | 2024-01-01 → 2024-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | −¥2.3bn | 2025-01-01 → 2025-06-30 | Cons. | Profit loss IFRS |
| Net income | −¥10m | 2024-01-01 → 2024-12-31 | Cons. | Profit loss IFRS (5-year summary) |
| Net income | −¥74m | 2024-01-01 → 2024-06-30 | Cons. | Profit loss IFRS |
| Total assets | ¥67.7bn | at 2025-06-30 | Cons. | Assets IFRS |
| Total assets | ¥71.9bn | at 2024-12-31 | Cons. | Assets IFRS |
| Total assets | ¥69.0bn | at 2024-06-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥29.4bn | at 2025-06-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥32.2bn | at 2024-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥38.3bn | at 2025-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥39.7bn | at 2024-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥40.0bn | at 2024-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥36.5bn | at 2023-12-31v | Cons. | Equity IFRS |
| Equity (owners) | ¥35.3bn | at 2025-06-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥36.4bn | at 2024-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥36.8bn | at 2024-06-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥10.5bn | at 2025-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥10.1bn | at 2024-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥16.3bn | at 2024-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥21.6bn | at 2023-12-31v | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | −¥932m | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | −¥3.2bn | 2024-01-01 → 2024-12-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | −¥1.5bn | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | ¥632m | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥10.4bn | 2024-01-01 → 2024-12-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥5.5bn | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | ¥1.4bn | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥694m | 2024-01-01 → 2024-12-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥186m | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥-18.19 | 2025-01-01 → 2025-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥21.96 | 2024-01-01 → 2024-12-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥6.61 | 2024-01-01 → 2024-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥-18.19 | 2025-01-01 → 2025-06-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥21.15 | 2024-01-01 → 2024-12-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥6.37 | 2024-01-01 → 2024-06-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 52.1% | at 2025-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 50.7% | at 2024-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 53.4% | at 2024-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 18
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q2r_E05712-000Medical Devicereportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥4.1bn |
| jpcrp040300-q2r_E05712-000Medical Devicereportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥4.1bn |
| jpcrp040300-q2r_E05712-000Medical Devicereportable segment | segment profit | 2025-01-01 → 2025-06-30 | ¥503m |
| jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥8.2bn |
| jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥8.2bn |
| jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segment | segment profit | 2025-01-01 → 2025-06-30 | −¥1.7bn |
| —segment total | revenue | 2025-01-01 → 2025-06-30 | ¥12.3bn |
| —segment total | revenue external | 2025-01-01 → 2025-06-30 | ¥12.3bn |
| —segment total | segment profit | 2025-01-01 → 2025-06-30 | −¥1.2bn |
| jpcrp040300-q2r_E05712-000Medical Devicereportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥2.6bn |
| jpcrp040300-q2r_E05712-000Medical Devicereportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥2.6bn |
| jpcrp040300-q2r_E05712-000Medical Devicereportable segment | segment profit | 2024-01-01 → 2024-06-30 | ¥676m |
| jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥9.1bn |
| jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥9.1bn |
| jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segment | segment profit | 2024-01-01 → 2024-06-30 | ¥1.1bn |
| —segment total | revenue | 2024-01-01 → 2024-06-30 | ¥11.7bn |
| —segment total | revenue external | 2024-01-01 → 2024-06-30 | ¥11.7bn |
| —segment total | segment profit | 2024-01-01 → 2024-06-30 | ¥1.8bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 716
| Item | Context | Value | Unit |
|---|---|---|---|
| Net increase decrease in short term borrowings fin cf IFRS | CurrentYTDDuration | -2175000000 | JPY |
| Repayments of long term borrowings fin cf IFRS | Prior1YTDDuration | -200000000 | JPY |
| Repayments of long term borrowings fin cf IFRS | CurrentYTDDuration | -200000000 | JPY |
| Proceeds from issuance of share acquisition rights fin cf IFRS | Prior1YTDDuration | 326000 | JPY |
| Proceeds from issuance of share acquisition rights fin cf IFRS | CurrentYTDDuration | 10440000 | JPY |
| Capital contribution from non controlling interests fin cf IFRS | Prior1YTDDuration | 628389000 | JPY |
| Capital contribution from non controlling interests fin cf IFRS | CurrentYTDDuration | 3288664000 | JPY |
| Payments for acquisition of interests in subsidiaries from non controlling interests fin cf IFRS | Prior1YTDDuration | -3269100000 | JPY |
| Payments for acquisition of interests in subsidiaries from non controlling interests fin cf IFRS | CurrentYTDDuration | － | JPY |
| Proceeds from exercise of share acquisition rights fin cf IFRS | Prior1YTDDuration | 474660000 | JPY |
| Proceeds from exercise of share acquisition rights fin cf IFRS | CurrentYTDDuration | 652856000 | JPY |
| Repayments of lease obligations fin cf IFRS | Prior1YTDDuration | -187874000 | JPY |
| Repayments of lease obligations fin cf IFRS | CurrentYTDDuration | -167214000 | JPY |
| Payments for purchase of treasury shares fin cf IFRS | Prior1YTDDuration | － | JPY |
| Payments for purchase of treasury shares fin cf IFRS | CurrentYTDDuration | -257000 | JPY |
| Net cash provided by used in financing activities IFRS | Prior1YTDDuration | -185598000 | JPY |
| Net cash provided by used in financing activities IFRS | CurrentYTDDuration | 1409490000 | JPY |
| Effect of exchange rate changes on cash and cash equivalents IFRS | Prior1YTDDuration | 1848584000 | JPY |
| Effect of exchange rate changes on cash and cash equivalents IFRS | CurrentYTDDuration | -700015000 | JPY |
| Net increase decrease in cash and cash equivalents IFRS | Prior1YTDDuration | -5326819000 | JPY |
| Net increase decrease in cash and cash equivalents IFRS | CurrentYTDDuration | 409879000 | JPY |
| Cash and cash equivalents IFRS | Prior2YearInstant | 21633028000 | JPY |
| Cash and cash equivalents IFRS | Prior1YearInstant | 10115037000 | JPY |
| Cash and cash equivalents IFRS | Prior1QuarterInstant | 16306208000 | JPY |
| Cash and cash equivalents IFRS | CurrentQuarterInstant | 10524916000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_jpcrp040300-q2r_E05712-000PharmaceuticalReportableSegmentMember | 9145014000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_jpcrp040300-q2r_E05712-000MedicalDeviceReportableSegmentMember | 2588807000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_ReportableSegmentsMember | 11733821000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration | 11733821000 | JPY |
| Revenue IFRS | Prior1YTDDuration_jpcrp040300-q2r_E05712-000PharmaceuticalReportableSegmentMember | 9145014000 | JPY |
| Revenue IFRS | Prior1YTDDuration_jpcrp040300-q2r_E05712-000MedicalDeviceReportableSegmentMember | 2588807000 | JPY |
| Revenue IFRS | Prior1YTDDuration_ReportableSegmentsMember | 11733821000 | JPY |
| Revenue IFRS | Prior1YTDDuration | 11733821000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration_jpcrp040300-q2r_E05712-000PharmaceuticalReportableSegmentMember | 1086200000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration_jpcrp040300-q2r_E05712-000MedicalDeviceReportableSegmentMember | 675942000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration_ReportableSegmentsMember | 1762142000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration | 1762142000 | JPY |
| Finance income IFRS | Prior1YTDDuration | 371879000 | JPY |
| Finance costs IFRS | Prior1YTDDuration | 1343366000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | Prior1YTDDuration | 40735000 | JPY |
| Profit loss before tax IFRS | Prior1YTDDuration | 831391000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_jpcrp040300-q2r_E05712-000PharmaceuticalReportableSegmentMember | 8194668000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_jpcrp040300-q2r_E05712-000MedicalDeviceReportableSegmentMember | 4057658000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_ReportableSegmentsMember | 12252326000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration | 12252326000 | JPY |
| Revenue IFRS | CurrentYTDDuration_jpcrp040300-q2r_E05712-000PharmaceuticalReportableSegmentMember | 8194668000 | JPY |
| Revenue IFRS | CurrentYTDDuration_jpcrp040300-q2r_E05712-000MedicalDeviceReportableSegmentMember | 4057658000 | JPY |
| Revenue IFRS | CurrentYTDDuration_ReportableSegmentsMember | 12252326000 | JPY |
| Revenue IFRS | CurrentYTDDuration | 12252326000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration_jpcrp040300-q2r_E05712-000PharmaceuticalReportableSegmentMember | -1682462000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |